EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Influence of USP15 and its derived-peptide on non-small cell lung cancer immune evasion via regulating PD-L1 stability

Di Wu, Ting Zeng, Ruo-Huang Lu, Wei Zhu, Qi Wen, Xue-Li Mao, Zheng-Zheng Yu, Guo-Xiang Lin, Yun-Xi Peng, Shan-Shan Lu, Hong Yi, Wei Huang und 2 weitere

Journal for ImmunoTherapy of Cancer · 2026-04 · 14 (4) · e014233

DOI: 10.1136/jitc-2025-014233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 01.04.2026. Verfasst von Di Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Tumor Escape. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) therapy targeting programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) shows promising clinical benefits in non-small cell lung cancer (NSCLC). However, the relatively low response rate highlights the need to elucidate the regulatory mechanism of PD-L1 expression, and develop an alternative strategy to target PD-1/PD-L1 immune checkpoint pathway. Our study focuses on the role and mechanism of ubiquitin-specific protease 15 (USP15) and its derived peptide U10 on NSCLC immune evasion.

Methods

USP15 as PD-L1’s deubiquitinase was identified by screening a human USP complementary DNA (cDNA) library. The role and mechanism of USP15 and its derived peptide U10 on PD-L1 stability in NSCLC cells were analyzed. T cell-mediated tumor cell killing activity and a syngeneic mouse NSCLC model were used to assess the influence of USP15 and U10 on NSCLC immune evasion. The antitumor effect of U10 in combination with PD-1 monoclonal antibody (mAb) via suppressing NSCLC immune evasion was also evaluated in mice. The expression and clinicopathological significance of USP15 and PD-L1 in cancer tissues were evaluated by immunohistochemistry.

Results

We identify USP15 as a novel deubiquitinase of PD-L1. Mechanistically, USP15 binds and stabilizes PD-L1 in NSCLC cells by inhibiting its ubiquitination and degradation. Functionally, USP15 inhibits T cell ability of killing NSCLC cells in vitro, and promotes NSCLC immune evasion in mice via decreasing the population and activation of CD8 + T cells in the tumor microenvironment. Based on the interacting regions of USP15 and PD-L1, we develop a 10 amino acid-long USP15-derived peptide U10, which successfully degrades PD-L1 via disrupting USP15 and PD-L1 interaction, dramatically suppresses NSCLC immune escape in vitro and in mice, and enhances the anti-NSCLC effect of PD-1 mAb in mice. Moreover, the expression levels of USP15 and PD-L1 are significantly higher in NSCLC than those in normal lung tissues and are positively correlated. The combination of USP15 and PD-L1 proteins was superior to individual proteins for predicting the efficacy of PD-1 mAb immunotherapy and patient prognosis in NSCLC.

Conclusion

Our findings reveal a critical role for USP15 in PD-L1 stability regulation and NSCLC immune escape and develop a novel peptide as an alternative strategy for ICIs therapy of NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenTumor EscapePeptidesHumansAnimalsMiceFemaleCell Line, TumorUbiquitin-Specific Proteases

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmune EvasionImmunotherapyLung CancerPD-L1PeptidesUSP15

Substanzen

B7-H1 AntigenCD274 protein, humanUSP15 protein, humanPeptidesUbiquitin-Specific Proteases

Autor:innen und Institutionen

  • Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • National Clinical Research Center of Geriatric Disorders (Xiangya Hospital), Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Oral Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China zhiqiangxiao@csu.edu.cn jinwupeng@csu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, D., Zeng, T., Lu, R. H., Zhu, W., Wen, Q., Mao, X. L., Yu, Z. Z., Lin, G. X., Peng, Y. X., Lu, S. S., Yi, H., Huang, W., Xiao, Z. Q., & Peng, J. (2026). Influence of USP15 and its derived-peptide on non-small cell lung cancer immune evasion via regulating PD-L1 stability. Journal for ImmunoTherapy of Cancer, 14(4), e014233. https://doi.org/10.1136/jitc-2025-014233

Vancouver

Wu D, Zeng T, Lu RH, Zhu W, Wen Q, Mao XL, et al. Influence of USP15 and its derived-peptide on non-small cell lung cancer immune evasion via regulating PD-L1 stability. Journal for ImmunoTherapy of Cancer. 2026;14(4):e014233. doi:10.1136/jitc-2025-014233

BibTeX
@article{Wu2026,
  author = {Wu, Di and Zeng, Ting and Lu, Ruo-Huang and Zhu, Wei and Wen, Qi and Mao, Xue-Li and Yu, Zheng-Zheng and Lin, Guo-Xiang and Peng, Yun-Xi and Lu, Shan-Shan and Yi, Hong and Huang, Wei and Xiao, Zhi-Qiang and Peng, Jinwu},
  title = {Influence of USP15 and its derived-peptide on non-small cell lung cancer immune evasion via regulating PD-L1 stability},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {e014233},
  doi = {10.1136/jitc-2025-014233}
}
Kostenlos starten →